ACAD Share Price Performance
US$0
-26.57 (-100.00%)
Price US$0
Fair ValueUS$33.25
Share Pricen/a
Seeking Alpha • Aug 24
ACADIA Pharmaceuticals Inc. Stock Price
- 4 Narratives written by author
- 3 Comments on narratives written by author
- 117 Fair Values set on narratives written by author
ACAD Community Narratives
AN
Fair Value
·Fair Value US$33.25 10.6% undervalued intrinsic discount
Global Outreach And Pipeline Programs Will Expand CNS Markets
0users have liked this narrative
0users have commented on this narrative
55users have followed this narrative
YI
Fair Value
·Fair Value US$28.75 3.4% overvalued intrinsic discount
ACADIA Pharmaceuticals: Navigating Growth at the Edge of Specialized Care
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
AN
Fair Value
·Fair Value US$20.58 44.5% overvalued intrinsic discount
Medicare Negotiations And Patent Cliffs Will Stifle Revenues
0users have liked this narrative
3users have commented on this narrative
5users have followed this narrative
ACADIA Pharmaceuticals: Navigating Growth at the Edge of Specialized Care
ACADIA Pharmaceuticals (NASDAQ: ACAD) occupies a narrow but important corner of the healthcare market. Unlike large-cap drugmakers chasing blockbuster indications, ACADIA focuses on highly specialized neurological and psychiatric conditions—areas where unmet need is significant and treatment options are limited.Read more
YI
US$28.75
3.4% overvalued intrinsic discount
Fair Value
Revenue
10.02% p.a.
Profit Margin
24.94%
Future PE
17.43x
Price in 2031
US$41.09
Secular Trends And Pipeline Expansion Will Drive CNS Therapy Adoption
ACADIA’s two main brain and rare-disease medicines appear to be gaining traction faster than many expect, with signs that growth outside the US could become a major driver. The bigger upside comes from several late-stage trials and possible new deals, but pricing pressure, competition, and clinical setbacks could quickly change the story.Read more
AN
US$47.18
37.0% undervalued intrinsic discount
Fair Value
Revenue
18.91% p.a.
Profit Margin
29.96%
Future PE
18.55x
Price in 2029
US$58.45
Global Outreach And Pipeline Programs Will Expand CNS Markets
ACADIA is trying to grow beyond its current best-selling brain and nerve medicines by reaching more patients outside major medical centers and pushing a much broader set of new treatments through testing. The upside comes from easier paths to approval and possible partnerships, but the story could change fast if its main drug runs into pricing pressure, new competition, or setbacks in the clinic.Read more
AN
US$33.25
10.6% undervalued intrinsic discount
Fair Value
Revenue
13.54% p.a.
Profit Margin
19.03%
Future PE
23.28x
Price in 2029
US$40.89
Medicare Negotiations And Patent Cliffs Will Stifle Revenues
ACADIA’s two lead drugs look strong today, but looming government price pressure and a big drop-off when patents expire could make future sales far less predictable. See why this cautious view argues the company may struggle to keep growing unless its next wave of treatments delivers.Read more
AN
US$20.58
44.5% overvalued intrinsic discount
Fair Value
Revenue
9.51% p.a.
Profit Margin
6.09%
Future PE
51.69x
Price in 2029
US$25.29
Trending Discussion
No trending discussion available.
Recently Updated Narratives
YI
ACADIA Pharmaceuticals: Navigating Growth at the Edge of Specialized Care
Fair Value: US$28.75 3.4% overvalued intrinsic discount
5 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ACAD: RADIANT Phase 2 Alzheimer’s Psychosis Data Will Drive Upside Potential
Fair Value: US$47.18 37.0% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ACAD: Future Upside Will Hinge On Alzheimer Psychosis Remlifanserin Data
Fair Value: US$33.25 10.6% undervalued intrinsic discount
55 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
ACADIA Pharmaceuticals Inc. Key Details
About ACAD
- Founded
- 1993
- Employees
- 797
- CEO
- WebsiteView website
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer’s disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington’s disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
